Cargando…
Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
OBJECTIVES: Most diffuse gliomas are reported to harbor isocitrate dehydrogenase (IDH) mutations. However, when these mutations are tested in clinical practice, the results are often negative. METHODS: This study examined the frequency of IDH1 and IDH2 mutations in gliomas classified according to th...
Autores principales: | Cho, Uiju, Yang, Seung Ho, Yoo, Changyoung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236789/ https://www.ncbi.nlm.nih.gov/pubmed/34162262 http://dx.doi.org/10.1177/03000605211019258 |
Ejemplares similares
-
Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022) -
Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022) -
CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021) -
Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021) -
Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)